Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
about
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapyThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesOptimizing pharmacologic management of inflammatory bowel disease.Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases.Comparative effectiveness of the biosimilar CT-P13.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.A systems pharmacology model for inflammatory bowel disease.Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel diseasePreparing for the incoming wave of biosimilars in oncology
P2860
Q28067631-121422CF-6842-4B53-985E-F130A5B6ABB9Q30397234-F6CA4F54-75CA-4C49-9B6D-2B1289E8F286Q33665611-2CF78992-E7D1-4B87-B26B-D1E9FB41980FQ38687407-C262BD4D-BBA0-4001-92C8-B61C7064EF93Q38699157-128F97F9-1795-4AA6-8EC0-3AE975154694Q38977625-DC0AD3CB-6214-4C5C-AFAF-F7F56005F05AQ39016810-6F66AA8E-BF16-4B58-969D-3DB265A40121Q39152159-A712829D-22FD-475C-A3DA-7128959217D2Q44581309-6A3BD3D0-FFB3-4192-9A47-47F78CBE973AQ47112883-8776BA43-32B6-4AEA-B003-1CA8319146FEQ47418286-1DBB5D53-176D-4D90-8373-3856F966E0C0Q47807650-C3B3718E-1DEA-4A08-BB25-9DFC04FF5DECQ48267381-A0BF49A1-E9C1-481E-BE2E-65647B76AFE0Q52364429-3BCC1C72-4106-4BF5-A91D-6D02D967AC2EQ57816058-D14F341A-738B-48B7-9E1D-8A9CA24EADABQ58762727-C6C313E1-F57B-40F0-B0EF-D860F265DDAB
P2860
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@ast
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@en
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@nl
type
label
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@ast
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@en
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@nl
prefLabel
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@ast
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@en
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@nl
P1476
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
@en
P2093
Shomron Ben-Horin
Stefan Schreiber
P356
10.1016/J.CGH.2016.05.023
P407
P577
2016-05-20T00:00:00Z